BPI-15086

BPI-15086 is an orally available, third-generation, ATP-competitive, irreversible small molecule inhibitor that selectively targets mutant forms of the epidermal growth factor receptor (EGFR), including the T790M resistance mutation. It is designed to overcome acquired resistance to earlier EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC) who have developed the T790M mutation after prior EGFR-TKI therapy. The drug has demonstrated safety and tolerability in phase I clinical trials and shows potential antineoplastic activity by inhibiting EGFR signaling pathways critical for tumor cell proliferation and survival[1][3][5].